Short Description

This assay helps to assess response to therapy and compares the efficacy of different therapeutic approaches. Detection of minimal residual disease level predicts progression free survival and overall survival after routine chemotherapy, after immunochemotherapy and after stem cell transplantation. The eradication of minimal residual disease in CLL predicts for improved outcome.

PreTest Information

Following information is mandatory: Sample time point (Chemotherapy time points); Previous diagnostic immunophenotype report; Clinical history and original TRF; Date and time when sample was drawn to be mentioned on the TRF; Therapy details.

Detail Description

Understanding Minimal Residual Disease (MRD) Monitoring for B-CLL

B-cell chronic lymphocytic leukemia (B-CLL) is a type of cancer that affects the blood and bone marrow. It is a slow-growing cancer that develops when the body produces too many abnormal white blood cells, which can crowd out healthy cells and lead to a weakened immune system. Although there is no cure for B-CLL, early detection and treatment can help manage the disease and improve quality of life.

One of the key tools used in the diagnosis and treatment of B-CLL is minimal residual disease (MRD) monitoring. MRD monitoring is a technique that allows doctors to track the number of cancer cells in a patient's blood or bone marrow after treatment. The goal of MRD monitoring is to determine whether a patient's cancer has gone into remission or is still active.

How is MRD Monitoring Performed?

MRD monitoring for B-CLL involves a simple blood test that measures the number of cancer cells in a patient's blood. The test is typically performed after treatment has been completed, and it can be repeated at regular intervals to monitor the patient's progress. In some cases, bone marrow biopsies may also be used to track MRD.

Why is MRD Monitoring Important for B-CLL Patients?

MRD monitoring is important for B-CLL patients because it allows doctors to track the effectiveness of treatment and make adjustments as needed. If MRD levels remain high after treatment, it may indicate that the cancer is still active and that additional treatment is needed. Conversely, if MRD levels are low or undetectable, it may indicate that the patient's cancer is in remission.

What are the Symptoms of B-CLL?

The symptoms of B-CLL can vary from person to person, and some people may not experience any symptoms at all. Common symptoms of B-CLL include:

• Fatigue
• Weakness
• Swollen lymph nodes
• Enlarged spleen
• Weight loss
• Fever
• Night sweats

If you are experiencing any of these symptoms, it is important to see a doctor for an evaluation.

Diagnosing B-CLL

B-CLL is typically diagnosed through a combination of blood tests, physical exams, and imaging studies. A doctor may order a complete blood count (CBC) to check for abnormalities in the blood, as well as a bone marrow biopsy to look for cancer cells. Imaging studies such as X-rays, CT scans, or MRIs may also be used to look for signs of cancer.

MRD Monitoring for B-CLL Test Cost

The cost of MRD monitoring for B-CLL can vary depending on a number of factors, including the location of the testing facility, the complexity of the test, and whether insurance covers the cost. At DNA Labs India, the cost of MRD monitoring for B-CLL is INR 17,000.

Conclusion

MRD monitoring is an important tool in the diagnosis and treatment of B-CLL. By tracking the number of cancer cells in a patient's blood or bone marrow, doctors can determine whether treatment is working and make adjustments as needed. If you are experiencing symptoms of B-CLL or have been diagnosed with the disease, it is important to work closely with your doctor to develop a treatment plan that includes regular MRD monitoring.

This assay helps to assess response to therapy and compares the efficacy of different therapeutic approaches. Detection of minimal residual disease level predicts progression free survival and overall survival after routine chemotherapy, after immunochemotherapy and after stem cell transplantation. The eradication of minimal residual disease in CLL predicts for improved outcome.